OTLK
NASDAQ
$1.38
Outlook Therapeutics Inc (OTLK)
Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company is headquartered in Cranbury, New Jersey.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $5.50 (+298.55%)
Market Cap
$163M
Free Cash Flow Yield
-28.83%
Beta (5Y)
0.95
Price Chart
Valuation
Market Cap$163M
Forward P/E2.85
P/S695.79
P/B38.42
Profitability
Total Revenue (TTM)$1.41M
Gross Profit (TTM)-$1.20M
EBITDA-$17M
Operating Margin-11007%
EPS-$1.11
Financial Health
Free Cash Flow Yield-28.83%
Growth & Risk
EPS 5Y CAGR-28.21%
FCF 5Y CAGR+1.77%
Beta (5Y)0.95
Sharpe Ratio0.56